Bausch Health’s Q1 revenues flat
Bausch Health’s sales were constrained by the Covid-19 pandemic but the global consumer and international prescription activities of its Bausch + Lomb eye care division posted strong growth. It expects a recovery from the latter part of the second quarter but nevertheless cut its full-year guidance.
Keep reading this article by becoming a member
Enjoy unrestricted access to Eyewear Intelligence
To continue reading this article subscribe now
- Unlimited access to our highly trusted industry insights and analysis
- Benchmark yourself against the market and competitors
- Find inspiration to drive your business forward
- Stay up to date with new business models and startups
If you aren’t ready to subscribe now, you can REGISTER FOR FREE. Already an Eyewear Intelligence subscriber? Sign in here.